Reprocessing single-use devices can cut supply costs and waste, but only when validation, labeling, and liability are treated as the product, not the paperwork around it.
Medical device interoperability is less a single technology purchase than an ongoing governance discipline, and the standards a hospital chooses today determine how much integration work it repeats tomorrow.
A drug-device combination product's regulatory fate is decided less by its clinical promise than by which FDA center gets named lead reviewer, and that determination deserves the same scrutiny a buyer gives any other structural risk factor.
Clear instructions for use are a design problem before they are a compliance problem, and manufacturers who treat IFU comprehension as an afterthought inherit avoidable field risk.
Medical device supply chains fail quietly at the single-source component, not at the finished-product line, and resilience planning has to start where the risk actually sits.
A device's pre-market trial answers whether it can work; post-market real-world evidence answers whether it does work, in the patients and settings the trial never enrolled.
Retiring a medical device is a data security and compliance event, not a facilities task, and treating it as the latter is where most exposure starts.
Data exchange is not only a technical connection. The operational test is whether the next action, owner, and evidence are visible.
A reading is useful only when someone owns the next step. The operational test is whether the next action, owner, and evidence are visible.
A matched record must still be verified. The operational test is whether the next action, owner, and evidence are visible.
Visibility comes before prioritization. The operational test is whether the next action, owner, and evidence are visible.
An API is part of the care pathway. The operational test is whether the next action, owner, and evidence are visible.